The concern of generic rivalry has repeatedly loomed around copyright’s iconic drug, Sildenafil, triggering questions about the outlook of related pharmaceutical investments. While initial times saw substantial profits, the exclusivity expiration has opened the path for discounted copies, potentially reducing revenue and posing a significant risk